This health tech stock is a buy and can surge nearly 50% from here, says Piper Sandler

Piper Sandler upgraded Oscar Health to overweight and raised its price target to $25 from $13, implying roughly 49% upside, after regional performance analysis in Miami‑Dade. The analyst argued Oscar has priced for and structured its CY26 product portfolio to withstand an expected expiration of enhanced advance premium tax credits (E‑APTCs) that could cut Individual ACA Marketplace enrollment ~20–30% (from ~24.3M to ~18.2M, a ~6.1M decline), highlighted new condition‑specific offerings (e.g., HelloMenu) that reduce underwriting risk and a broker bonus program to shift sales into November; shares are up ~24% YTD.

Analysis

Market structure: Oscar (OSCR) is positioned to win concentrated share and margin expansion if E-APTCs expire end-CY25 because it has priced and re‑engineered 2026 product tiers (buy‑down options, condition-specific offerings) to retain members and raise effective premiums. Direct beneficiaries include digital-first, vertically integrated carriers and brokers (who get November bonuses); losers are incumbents without targeted retention products or flexible metal‑level pricing who face higher acquisition cost and adverse selection. Expect 2026 ACA market volume to fall ~25% (24.3M → 18.2M) which concentrates profitable lives and lifts pricing power for survivors, but total premium dollars could still compress if membership loss > share gains.

Risk assessment: Key tail risks—Congress or CMS extends subsidies (major downside to OSCR’s margin recovery thesis), regulatory scrutiny on broker incentives, and weaker-than-expected engagement with HelloMenu that fails to lower claims. Time buckets: immediate (days) — headline sensitivity around Piper upgrade and flows; short (weeks/months) — November enrollment and weekly CMS snapshots; long (quarters) — CY26 underwriting results and 10‑K/CMS rule changes by Dec‑2025. Hidden dependencies include broker economics (bonuses may raise CAC) and provider network rates that can erode margin recapture.

Trade implications: Tactical play is long OSCR into November enrollment flow and through Jan‑2026 (when CY26 pricing/retention shows up), while using defined‑risk option structures to cap cost. Consider size limits (2–6% thesis weight) and hedges against subsidy extension. Sector rotation: overweight digital/individual-market carriers, underweight legacy book insurers that lack targeted retention tools.

Contrarian angles: Consensus assumes expiration occurs and benefits winners; the market underprices the extension tail—if subsidies extend, OSCR may underperform as its adverse‑case pricing looks suboptimal. Also, broker bonus could be a short‑term net negative (higher CAC) before retention benefits appear. Historical parallel: 2017–2018 ACA pricing cycles where policy reversals created rapid reversals in insurer profitability — expect binary moves around legislative/CMS news.

Key Decisions for Investors

• Establish a 2–3% long position in OSCR common stock ahead of November enrollment activity (open positions by end‑October); increase to 4–6% if OSCR share price drops below $18 or weekly broker‑reported new enrollments for OSCR exceed +15% MoM in at least two consecutive weekly CMS snapshots (validation of market share capture).
• Buy a Jan 2026 OSCR 20/30 call spread (~50% notional of the equity position) to capture upside to Piper’s $25 PT while limiting premium outlay; take profits on the spread at +100% or if OSCR >= $30, cut losses at -50% of premium paid.
• Put on a policy tail hedge: purchase Jan 2026 OSCR $15 puts sized ~25% of equity exposure if Congressional/CMS signals within next 60 days indicate active debate on subsidy extension (monitor House/Senate bill text and HHS bulletins); exit puts if subsidy extension is passed or if put premium declines 60%.
• Construct a relative‑value pair: long OSCR (2%) vs short Centene (CNC) (2%) through Jan‑2026 to express a bet that digital/individual‑market share winners outperform Medicaid/legacy players; rebalance or close by earnings Q4 2025 or upon definitive CMS/subsidy guidance.